



Market Trend



SOFIX increased by 4% on weekly basis supported by most of its components and mainly by Chimimport (6C4) and Central Cooperative Bank (4CF). The index rapidly soared and probably the level will be unsustainable as the individual investors will prefer to lock profits. The picture is the same as at the beginning of 2012 when the market increased and then stayed on hold for a long period. We expect some recent weakness but the long-term expectations are positive.

Trading Activity



The week began in the usual mood but on the sudden interest toward the blue-chips boosted the turnover. Chimimport (6C4) was the most traded position and the share jumped in improved volumes. The activity decreased at the end of the week as the institutional investors stepped back.

WEEKLY BULLETIN
11 January 2013
SOFIX

Stock	Last Price	Weekly Change	Bid	Ask
Advance Terrafund REIT	2.27	-0.83%	2.26	2.30
Bulgartabac Holding	85.90	7.38%	84.00	89.90
Corporate Commercial Bank	81.50	-3.49%	81.50	83.99
Central Cooperative Bank	0.81	39.07%	0.81	0.81
Chimimport	1.30	41.92%	1.28	1.31
Neochim	30.00	1.39%	29.31	30.00
M+S Hydraulic	7.00	-0.43%	6.86	7.00
Eurohold Bulgaria	1.02	2.30%	1.02	1.06
First Investment Bank	1.78	21.09%	1.75	1.77
Industrial Holding Bulgaria	0.80	13.71%	0.76	0.80
Kaolin	3.23	-4.69%	3.23	3.30
Monbat	4.70	0.73%	4.70	4.81
Sopharma	2.08	1.46%	2.07	2.08
Stara Planina Hold	2.54	-2.23%	2.54	2.60
Bulgaria Real Estate Fund REIT	0.54	1.89%	0.54	0.54

The most of SOFIX components soared in double-digit percent on weekly basis. The modest increase of Bulgartabac Holding (57B) on the background of the other components, cause the 4% increase of the main index. Kaolin (6K1) and Corporate Commercial Bank (6C9) lagged behind the overall euphoria and probably will try to catch up in short term. The worries from the large investor exit of some positions are aside at the moment.

News

- 07 January 2013:** The Board of Directors of Sopharma (3JR) has notified that from December 20 2012 up to January 02 2013 the Company has bought back 1 700 own shares at the total value of BGN 3 631.00 as the average repurchase price has been BGN 2.14 per share. After this transaction, the total number of bought-back shares has reached 3 487 931 shares, representing 2.64% of the share capital of the company.
- 09 January 2013:** On January 03 2013, the Central Depository has registered the new issue of shares under the capital increase of Zarneni Hrani Bulgaria (T43) as a result of the completed procedure for transformation of the company through merger of Chimimport Group into Zarneni Hrani Bulgaria.
- 11 January 2013:** For December 2012, Sopharma (3JR) has realised a decrease in its sales by 13% when compared to the same month of the preceding year, including a 9% decrease of the sales on the domestic market and a 17% decrease in the export sales. The proceeds from sales for 2012 have increased by 0.35%, including a 9% reduction on the domestic market and a 5% increase in the export sales when compared to 2011.

Disclaimer

Analyst Certification: The research analyst(s) certifies that: (1) all of the views expressed in this document accurately reflect his or her personal views about any and all of the subject securities or issuers; (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this document.

Financial Interest: ELANA Trading may trade or own shares of the analyzed companies. The research analyst(s) is not holding shares of the analyzed companies, unless otherwise noted.

Regulatory Authority: Financial Supervisory Commission, *Shar Planina* Street 33, 1303 Sofia, Bulgaria

Information Disclosure: All reasonable care has been taken to ensure the facts stated are accurate and opinions given are fair and reasonable. Our recommendations are based on information available to the public that we consider to be reliable but for the completeness and accuracy of which we assume no liability. Neither ELANA Trading, nor its directors, officers or employees shall in any way be responsible for its contents. The views expressed may differ from the views of other firm departments or representatives. Additional information is available upon request. Unless otherwise noted, sources for all information in charts and tables are ELANA Trading's calculations.

Risks for Investors: Information in this document should not be regarded as an offer to buy or sell any financial instruments. The investment possibilities discussed in this document may not be suitable for certain investors depending on their specific investment objectives and time horizon or in the context of their overall financial situation. In particular, the risks associated with an investment in the securities or the financial instruments under discussion are not explained in its entirety.

The prices or values of the securities may go down as well as up and can fluctuate and fall against the investor. The securities or investments may cause the investor to lose the amount invested. Past performance is not a guide to future performance. Changes in exchange rates may have an adverse effect on the value, price or income of the securities or investments.

Valuation Methods: Company valuations are based on the following methods: multiple-based (P/E, P/B, EV/EBITDA), historical valuation approaches, peer comparisons, discount models (DCF, DDM) or asset-based evaluation methods. Valuation models are dependent on macroeconomic factors, including interest rates, foreign exchange rates, prices of raw materials, and any expectations about the economy, the market sentiment. The valuation is based on expectations that might change rapidly and without notice, depending on developments specific to individual industries and countries. Recommendations and target prices derived from the models might therefore change accordingly. The application of models depends on forecasts of a range of economic variables, thus there is a range of reasonable variations within models. Any valuation is dependent upon inputs that are based on the subjective opinion of the analysts carrying out this valuation.

Recommendations: Analyst(s) recommendations are based on the specific factors for the company, sector, country and global developments, as compared to market indices. Recommendations and opinions reflect ELANA Trading's expectations over the 12-month period following publication from the perspective of long-only investment clients. ELANA Trading reserves the right to express different or contrary recommendations and opinions for different timescales or for other types of investment client. Except as otherwise noted, expected performance over next 12 months vary for different recommendations for Bulgarian stocks as follows:

Outperform	More than 5% higher as compared to SOFIX and BG40 performance
Market Perform	Market performance, +/-5% as compared to SOFIX and BG40
Underperform	More than 5% lower as compared to SOFIX and BG40 performance

Frequency of Recommendations: No schedule of recommendations is available. The frequency of recommendations depends on specific factors to individual companies and the opinion of the analyst(s) for the necessity of minor or major changes.

For more information, please contact:

Research analyst
Tsvetoslav Tsachev
Tamara Becheva

Phone:
+359 2 810 00 23
+359 2 810 00 27

E-mail:
tsachev@elana.net
becheva@elana.net

Internet:
www.elana.net
www.elana.net